Charite-University Medicine Investigator Leads Novartis Study Evidencing Superiority for Addressing the Hives

Novartis is sponsoring a global clinical trial led by an investigator with Charite-University Medicine, Berlin Germany—along with over a hundred other sites they are in hot pursuit of a new treatment for patients with chronic hives. Thus far clinical trials of the drug ligelizumab, targeting the immune system antibody called immunoglobulin E (IgE) which is responsible for the allergic relation behind the hives, shows significant promise.

The Background

Reported in US News and World Report’s Dennis Thompson, the sponsor Novartis seeks to make ligelizumab available for those suffering from the hives. A very common condition—a temporary allergic reaction to a drug, food or substance—one out of 200 people will ultimately succumb to a case of chronic hives during their lifetime. It is being compared against potential competitor omalizumab produced by Genentech (Roche). Recent studies are favoring ligelizumab. Omalizumab is pricey and it is anticipated that ligelizumab will be costly as well---but if it is approved it may work better.


Also known as urticaria, it is a skin rash with red, raised, itchy bumps. They can burn or sting—it can be incredibly unpleasant to painful. They...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee